70 related articles for article (PubMed ID: 7750809)
1. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo.
Stocchi F; Barbato L; Bramante L; Bonamartini A; Ruggieri S
Funct Neurol; 1994; 9(5):259-64. PubMed ID: 7750809
[TBL] [Abstract][Full Text] [Related]
2. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
3. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden CD; Agnoli A
Mov Disord; 1992; 7(3):249-56. PubMed ID: 1620143
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.
Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA
Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966
[TBL] [Abstract][Full Text] [Related]
7. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
9. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
11. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
12. A trial of dextromethorphan in parkinsonian patients with motor response complications.
Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
[TBL] [Abstract][Full Text] [Related]
13. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
[TBL] [Abstract][Full Text] [Related]
14. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Bergemann N; Baas H; Fischer PA
Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Blindauer K; Shoulson I; Oakes D; Kieburtz K; Schwid S; Fahn S; Stern M; Goetz C; Nutt J; Goren S; Sayag N; Scolnik M; Levy R; Eyal E; Salzman P; Pagano M;
Arch Neurol; 2006 Feb; 63(2):210-6. PubMed ID: 16476809
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
[TBL] [Abstract][Full Text] [Related]
17. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
[TBL] [Abstract][Full Text] [Related]
20. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]